NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ProJenX, Inc.

ProJenX, Inc.

Private
Nissequogue, New YorkHealthcare & Life Scienceshttps://projenx.com/

Last Round

Grant

Jun 20, 2024

Total Funding Raised

$21.1M

Company Overview

ProJenX, Inc. is a biotechnology company that develops novel, brain-penetrant, targeted therapies for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

amyotrophic lateral sclerosisALSbiotechnologydrug discoveryMAP4K inhibitorclinical trialsneurodegenerative diseaseblood-brain barrierdigital twinbiotech startupclinical-stage biotechsmall molecule drugprecision medicinetherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProJenX, Inc. Comparables

Compare ProJenX, Inc. with similar companies based on industry and business-model similarity.

ProJenX, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
QurAlis
84%
Trace Neuroscience
82%
Spinogenix, Inc.
82%

ProJenX, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 20, 2024
Series ANov 2, 2023
SeedFeb 16, 2022

Key People

Founding team and executive leadership

Stan Abel

President and Chief Executive Officer

Executive Team

Erin Fleming

Chief Operating Officer

Executive Team

ProJenX, Inc. Investors

Notable investors and investment history

ProJenX, Inc. investors
InvestorRounds
The ALS AssociationGrant
Medical Excellence CapitalSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2024

    $1M grant received from The ALS Association.

ProJenX, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ProJenX, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ProJenX, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNissequogue, New York
Employee Range9
Year Founded2021
Last FundingJun 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.